Drug Targets for Head and Neck Cancer
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 256
Special Issue Editors
Interests: head and neck cancer treatment; endoscopic surgery; basic research for head and neck
Special Issues, Collections and Topics in MDPI journals
Interests: apoptosis; autophagy; metastasis; anti-cancer; nature compound; cell biochemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The term head and neck cancers refers to variations of the disease that usually begin in the squamous cells that line the mucosal epithelium of the upper aerodigestive tract (nasal cavity, oral cavity, oropharynx, pharynx, hypopharynx, and larynx), and also includes the cutaneous malignancies of the head and neck region, as well as malignant tumors arising from different cell types of the thyroid and salivary glands. It constitutes the sixth most common malignancy in the world and, in recent years, the incidence of this cancer is slowly and consistently increasing. Due to its multi-facted intricacies involving both the head and neck region, symptoms can often be mild and it is hard to detect the cancer at the early stage. If caught at a later stage, the chances of survival are low. The overall 5-year survival rate for head and neck cancers is approximately 50%. Thus, its treatment remains one of the major challenges of modern medicine. This Special Issue welcomes research articles and review papers focused on pathogenetic, chemoresistance, drug targets molecular biology and therapeutic perspectives in head and neck cancer, from basic translational science studies to clinical research. All authors are invited to send their research related to the topic of our Special Issue, both original and review articles, to be assessed and included in the peer review process of our journal.
Prof. Dr. Mu-Kuan Chen
Dr. Ming-Ju Hsieh
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- head and neck cancer
- oral cancer
- genetic biomarkers
- drug therapeutic target
- molecular pathology
- molecular biology
- chemoresistance
